Literature DB >> 12095063

Increased access to transplantation for blood group B cadaveric waiting list candidates by using A2 kidneys: time for a new national system?

Paul W Nelson1, Charles F Shield, Nicolas A Muruve, Daniel Murillo, Bradley A Warady, Mark I Aeder, Christopher F Bryan.   

Abstract

Since blood group B end-stage renal disease (ESRD) patients have less access to donor kidneys and a higher minority composition than any other blood group, the United Network for Organ Sharing (UNOS) approved a voluntary national kidney allocation variance to allow organ procurement organizations (OPOs) to preferentially allocate A2 and A2B kidneys to B candidates. The Midwest Transplant Network OPO has preferentially allocated and transplanted kidneys from blood group A2 and A2B donors to our blood group B waiting list candidates for more than 7 years to increase access to kidneys for the B candidates on our OPO-wide waiting list. Between 1994 and 2000, a total of 121 blood group B ESRD patients from our OPO-wide cadaveric kidney waiting list were transplanted. Thirty-four per cent (41/121) of those B candidates received either an A2 or an A2B kidney. One- and 5-year graft survival rates for the group of B recipients of A2 or A2B kidneys were 91 and 85% (died with functioning graft [DWFG] censored), respectively, which were not significantly different from those of 91 and 80% for the 80 B recipients of B or O kidneys (Wilcoxon = 0.48; log-rank = 0.55). These data support the national trial for additional OPOs to voluntarily allocate A2 and A2B kidneys preferentially to B waiting list candidates, thus increasing access of blood group B patients to renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095063     DOI: 10.1034/j.1600-6143.2002.020115.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  Underutilization of A2 ABO incompatible kidney transplantation.

Authors:  Robert R Redfield; Ronald F Parsons; Eduardo Rodriguez; Moiz Mustafa; James Cassuto; Kumar Vivek; Hooman Noorchashm; Ali Naji; Matthew H Levine; Peter L Abt
Journal:  Clin Transplant       Date:  2011-10-27       Impact factor: 2.863

2.  Impact of the new kidney allocation system A2/A2B → B policy on access to transplantation among minority candidates.

Authors:  Paulo N Martins; Margaux N Mustian; Paul A MacLennan; Jorge A Ortiz; Mohamed Akoad; Juan Carlos Caicedo; Gabriel J Echeverri; Stephen H Gray; Reynold I Lopez-Soler; Ganesh Gunasekaran; Beau Kelly; Constance M Mobley; Sylvester M Black; Carlos Esquivel; Jayme E Locke
Journal:  Am J Transplant       Date:  2018-03-31       Impact factor: 8.086

Review 3.  Non-medical factors influencing access to renal transplantation.

Authors:  Eszter Panna Vamos; Marta Novak; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-04-07       Impact factor: 2.370

4.  [Extending the donor pool in renal transplantation].

Authors:  J Jones; C Hampel
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

5.  Effects of Neutralization by Soluble ABH Antigens Produced by Transplanted Kidneys From ABO-Incompatible Secretor Donors.

Authors:  Jieun Kim; Sinyoung Kim; In Sik Hwang; Jong Rak Choi; Jae Geun Lee; Yu Seun Kim; Myoung Soo Kim; Hyun Ok Kim
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

6.  Factors affecting mortality during the waiting time for kidney transplantation: A nationwide population-based cohort study using the Korean Network for Organ Sharing (KONOS) database.

Authors:  Sunhwa Lee; Kyung Don Yoo; Jung Nam An; Yun Kyu Oh; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee
Journal:  PLoS One       Date:  2019-04-12       Impact factor: 3.240

7.  A Safe Anti-A2 Titer for a Successful A2 Incompatible Kidney Transplantation: A Single-center Experience and Review of the Literature.

Authors:  Yorg Azzi; Gayatri Nair; Pablo Loarte-Campos; Maria Ajaimy; Jay Graham; Luz Liriano-Ward; Cindy Pynadath; Joan Uehlinger; Michael Parides; Alesa Campbell; Adriana Colovai; Omar Alani; Marie Le; Stuart Greenstein; Milan Kinkhabwala; Juan Rocca; Enver Akalin
Journal:  Transplant Direct       Date:  2021-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.